Jefferies Maintains a 'Hold' on Amedisys (AMED); Raises Numbers To Reflect Benefit Of Agency Rationalization Efforts
Tweet Send to a FriendGet Alerts AMED Hot Sheet
Price: $13.41 --0%
Rating Summary:
0 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Rating Summary:
0 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Trade AMED Now!
Jefferies maintains a 'Hold' on Amedisys (NASDAQ: AMED) price target raised from $11 to $16.50.
Analyst, Arthur I. Henderson, said, "We expect AMED to realize a $20MM earnings benefit this year from its agency consolidation efforts in 4Q11 and incremental cost containmnet initiatives. While we commend mgmt for their ability to adapt to ongoing Medicare rate reductions and soft volume trends, we believe that share price upside is dependent on AMED's ability to re-establish a track record of volume growth this year."
Other highlighted points include: 1) Lots of moving parts, but Q4 initiatives should benefit 2012; 2) We're adjusting our FY12 estimates to reflect improved volume expectations and lower case mix cut impact; and 3) It's quiet on the reimbursement front for now, but turbulence could reemerge after the elections.
FY12 EPS estimate raised from $0.97 to $1.00 and FY13 from $0.80 to $0.90.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Shares of Amedisys closed at $14.06 yesterday, with a 52 week range of $9.12-$36.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Arthur I. Henderson, said, "We expect AMED to realize a $20MM earnings benefit this year from its agency consolidation efforts in 4Q11 and incremental cost containmnet initiatives. While we commend mgmt for their ability to adapt to ongoing Medicare rate reductions and soft volume trends, we believe that share price upside is dependent on AMED's ability to re-establish a track record of volume growth this year."
Other highlighted points include: 1) Lots of moving parts, but Q4 initiatives should benefit 2012; 2) We're adjusting our FY12 estimates to reflect improved volume expectations and lower case mix cut impact; and 3) It's quiet on the reimbursement front for now, but turbulence could reemerge after the elections.
FY12 EPS estimate raised from $0.97 to $1.00 and FY13 from $0.80 to $0.90.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Shares of Amedisys closed at $14.06 yesterday, with a 52 week range of $9.12-$36.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Citi Raises PT on Micron Technology (MU) to $19
- UPDATE: Global Equities Starts Tesla Motors (TSLA) at Overweight
- AMA Proposal 409 Contains No New Info, Monster Beverage (MNST) Sell-Off 'Overdone'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & Co, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
